For more information or confidential assistance
800-306-3180
se habla español

Androgel Lawsuits Identified for Bellwether Trial Pool

The first bellwether trials in multidistrict litigation 2545, which concerns injuries allegedly caused by testosterone replacement therapy, are slated to go to trial by fall of 2016. Court dockets show that more than 2,700 complaints are currently pending against the manufacturers of Testim, Adroderm, Androgel, Axiron and other products that... Read more »

Study Examines Testosterone Dosage and Heart Risks

Byetta pancreatic cancer patient
In July, researchers from the University of North Carolina at Chapel Hill published a study on testosterone heart risks in the medical journal, JAMA Internal Medicine, finding that the side effects of testosterone injections may pose the highest risk of cardiovascular events, hospitalizations and deaths. The team examined the comparative... Read more »

Does Testosterone Therapy Contribute to Atherosclerosis?

Byetta pancreatic cancer patient
The use of testosterone replacement therapy (TRT) has been increasing, yet some have expressed concerns about potentially life-threatening side effects of testosterone gels, creams, patches, and other products. Cardiovascular complications are of particular concern. Some men have filed lawsuits against a handful of TRT product manufacturers, claiming that the drugs... Read more »

Testosterone Injury Lawsuits Approach 2,000 Mark

The number of product liability complaints regarding testosterone replacement therapy continues to skyrocket, with allegations that the products caused heart attacks, stroke, and debilitating blood clot injuries. Men who took supplements such as Axiron, Testim and Androgel are seeking fair compensation and justice through the legal system, based on counts... Read more »

Is “Low T” a Real Condition? FDA Weighs In

Propecia erectile dysfunction patient
Over the past several years, the number of testosterone replacement therapy products prescribed to men approaching senior citizen status has literally soared – reaching sales topping $9 billion. The culprit? The apparent onset of the condition known as “low-t,” or low testosterone – a condition believed by some in the... Read more »